GSK Confident Its ‘Last Drug Standing’ In Anemia Class Can Gain US Panel Backing

Safety Profile Will Be Closely Scrutinized

 
• By Andrew McConaghie
  
US FDA entrance sign
Daprodustat will be the third HIF-PHI reviewed by the FDA ad comm, GSK hoping its drug will succeed where rivals failed. • Source: Sutterstock, JHVEPhoto
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip